Key result
A positive oral flecainide challenge test in right-sided precordial leads (V1R-V3R) was significantly associated with the development of malignant symptoms in Brugada patients.
Why the study?
Does a positive flecainide challenge test in right-sided precordial leads predict poor prognosis in patients with type 2 or 3 Brugada ECG patterns?
Cohort (n=126)
No
Does a positive flecainide challenge test in right-sided precordial leads predict poor prognosis in patients with type 2 or 3 Brugada ECG patterns?
A positive flecainide challenge test in right-sided precordial leads (V1R-V3R) predicts a poorer prognosis in patients with type 2 or 3 Brugada ECG patterns, potentially aiding in risk stratification for ICD implantation.
Answers are grounded in this paper and cite their sources.
May inform risk stratification in type 2/3 Brugada patterns; leaves open whether right-sided flecainide challenge should guide ICD decisions.
BACKGROUND: The Brugada syndrome is a heterogeneous genetic disease that predisposes to life-threatening ventricular tachyarrhythmias and sudden cardiac death (SCD). The only proven way to prolong the survival of patients with Brugada syndrome is to implant an implantable cardioverter-defibrillator (ICD). This should be implanted for high-risk patients only. METHOD: The patients with type 2 or 3 Brugada ECG pattern were selected for the study. We evaluated 126 patients with Brugada type ECG patterns. Nineteen patients had positive response. Those who had positive result in right side located leads had poorer prognosis. CONCLUSION: Positive flecainide challenge test in right side located pericordial leads can be used as a predictor of poor prognosis in Brugada patients. This can be evaluated in another research for its role in the implantation of ICD. Also, the oral flecainide is not sensitive enough to rule out the presence of Brugada syndrome and it should not be trusted as a screening test for suspected cases.
No takes yet. Share an insight, caveat, or question.
Hashemi et al. (2013) conducted a cohort in Brugada syndrome (Type 2 or 3 ECG pattern) (n=126). Positive flecainide challenge test in right-sided precordial leads (V1R-V3R) vs. Negative flecainide challenge test in right-sided precordial leads was evaluated on Malignant symptoms (SCD, true syncope, or documented ventricular arrhythmia) (p=0.037). A positive oral flecainide challenge test in right-sided precordial leads (V1R-V3R) was significantly associated with the development of malignant symptoms in Brugada patients.
Synapse has enriched 10 related papers. Consider them for comparative context: